GSK plc (GSK) - Net Assets

Latest as of June 2026: GBX17.18 Billion GBX ≈ $2.09 Million USD

Based on the latest financial reports, GSK plc (GSK) has net assets worth GBX17.18 Billion GBX (≈ $2.09 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX61.74 Billion ≈ $7.51 Million USD) and total liabilities (GBX44.56 Billion ≈ $5.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See how leveraged is GSK plc's balance sheet to measure how much of total assets are equity-financed.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX17.18 Billion
% of Total Assets 27.82%
Annual Growth Rate 7.0%
5-Year Change -25.24%
10-Year Change 221.5%
Growth Volatility 102.64

GSK plc - Net Assets Trend (1986–2025)

This chart illustrates how GSK plc's net assets have evolved over time, based on quarterly financial data. Also explore GSK plc (GSK) net asset momentum to track the company's year-over-year net asset growth rate.

Annual Net Assets for GSK plc (1986–2025)

The table below shows the annual net assets of GSK plc from 1986 to 2025. For live market cap and overall valuation, see GSK plc market cap and net worth.

Year Net Assets Change
2025-12-31 GBX15.96 Billion
≈ $1.94 Million		 +21.93%
2024-12-31 GBX13.09 Billion
≈ $1.59 Million		 +2.27%
2023-12-31 GBX12.79 Billion
≈ $1.56 Million		 +26.73%
2022-12-31 GBX10.10 Billion
≈ $1.23 Million		 -52.69%
2021-12-31 GBX21.34 Billion
≈ $2.60 Million		 +2.57%
2020-12-31 GBX20.81 Billion
≈ $2.53 Million		 +13.35%
2019-12-31 GBX18.36 Billion
≈ $2.23 Million		 +399.92%
2018-12-31 GBX3.67 Billion
≈ $446.78K		 +5.25%
2017-12-31 GBX3.49 Billion
≈ $424.51K		 -29.70%
2016-12-31 GBX4.96 Billion
≈ $603.85K		 -44.10%
2015-12-31 GBX8.88 Billion
≈ $1.08 Million		 +79.86%
2014-12-31 GBX4.94 Billion
≈ $600.57K		 -36.82%
2013-12-31 GBX7.81 Billion
≈ $950.49K		 +15.96%
2012-12-31 GBX6.74 Billion
≈ $819.70K		 -23.68%
2011-12-31 GBX8.83 Billion
≈ $1.07 Million		 -9.42%
2010-12-31 GBX9.74 Billion
≈ $1.19 Million		 -9.28%
2009-12-31 GBX10.74 Billion
≈ $1.31 Million		 +29.14%
2008-12-31 GBX8.32 Billion
≈ $1.01 Million		 -16.14%
2007-12-31 GBX9.92 Billion
≈ $1.21 Million		 +2.85%
2006-12-31 GBX9.64 Billion
≈ $1.17 Million		 +27.43%
2005-12-31 GBX7.57 Billion
≈ $920.86K		 +23.11%
2004-12-31 GBX6.15 Billion
≈ $748.02K		 -27.28%
2003-12-31 GBX8.45 Billion
≈ $1.03 Million		 +14.43%
2002-12-31 GBX7.39 Billion
≈ $898.91K		 -12.02%
2001-12-31 GBX8.40 Billion
≈ $1.02 Million		 -6.23%
2000-12-31 GBX8.96 Billion
≈ $1.09 Million		 +180.46%
1999-12-31 GBX3.19 Billion
≈ $388.50K		 +15.35%
1998-12-31 GBX2.77 Billion
≈ $336.79K		 +46.46%
1997-12-31 GBX1.89 Billion
≈ $229.96K		 +49.17%
1996-12-31 GBX1.27 Billion
≈ $154.16K		 +473.30%
1995-12-31 GBX221.00 Million
≈ $26.89K		 -61.54%
1995-06-30 GBX574.69 Million
≈ $69.92K		 -88.84%
1994-06-30 GBX5.15 Billion
≈ $626.48K		 +10.56%
1993-06-30 GBX4.66 Billion
≈ $566.62K		 +27.97%
1992-06-30 GBX3.64 Billion
≈ $442.76K		 +10.88%
1991-06-30 GBX3.28 Billion
≈ $399.32K		 +17.01%
1990-06-30 GBX2.81 Billion
≈ $341.29K		 +21.27%
1989-06-30 GBX2.31 Billion
≈ $281.43K		 +28.29%
1988-06-30 GBX1.80 Billion
≈ $219.37K		 +23.16%
1987-06-30 GBX1.46 Billion
≈ $178.13K		 +33.09%
1986-06-30 GBX1.10 Billion
≈ $133.84K		 --

Equity Component Analysis

This analysis shows how different components contribute to GSK plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1020900000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings GBX10.21 Billion 62.34%
Common Stock GBX1.35 Billion 8.24%
Other Components GBX4.82 Billion 29.43%
Total Equity GBX16.38 Billion 100.00%

GSK plc Competitors by Market Cap

The table below lists competitors of GSK plc ranked by their market capitalization.

Company Market Cap
Osisko Gold Group Inc.
NYSE:OGG
 $853.22 Million
ShuYu Civilian Pharmacy Corp. Ltd.
SHE:301017
 $853.50 Million
MBK Public Company Limited
BK:MBK
 $853.81 Million
Liaoning Oxiranchem Inc
SHE:300082
 $853.88 Million
Joeone Co Ltd
SHG:601566
 $852.65 Million
Shenzhen Sunshine Laser & Electronics Technology Co Ltd
SHE:300227
 $852.61 Million
Zhejiang Jingxing Paper Joint Stock Co Ltd
SHE:002067
 $852.48 Million
Bata India Limited
NSE:BATAINDIA
 $852.40 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in GSK plc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 13,671,000,000 to 16,377,000,000, a change of 2,706,000,000 (19.8%).
  • Net income of 5,716,000,000 contributed positively to equity growth.
  • Dividend payments of 2,564,000,000 reduced retained earnings.
  • Share repurchases of 1,377,000,000 reduced equity.
  • New share issuances of 15,000,000 increased equity.
  • Other comprehensive income decreased equity by 1,451,000,000.
  • Other factors increased equity by 2,367,000,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income GBX5.72 Billion +34.9%
Dividends Paid GBX2.56 Billion -15.66%
Share Repurchases GBX1.38 Billion -8.41%
Share Issuances GBX15.00 Million +0.09%
Other Comprehensive Income GBX-1.45 Billion -8.86%
Other Changes GBX2.37 Billion +14.45%
Total Change GBX- 19.79%

Book Value vs Market Value Analysis

This analysis compares GSK plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 439.93x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 3801.83x to 439.93x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1986-06-30 GBX0.46 GBX1750.00 x
1987-06-30 GBX0.61 GBX1750.00 x
1988-06-30 GBX0.75 GBX1750.00 x
1989-06-30 GBX0.96 GBX1750.00 x
1990-06-30 GBX0.57 GBX1750.00 x
1991-06-30 GBX0.67 GBX1750.00 x
1992-06-30 GBX0.74 GBX1750.00 x
1993-06-30 GBX0.94 GBX1750.00 x
1994-06-30 GBX1.03 GBX1750.00 x
1995-06-30 GBX0.08 GBX1750.00 x
1995-12-31 GBX0.02 GBX1750.00 x
1996-12-31 GBX0.22 GBX1750.00 x
1997-12-31 GBX0.32 GBX1750.00 x
1998-12-31 GBX0.46 GBX1750.00 x
1999-12-31 GBX0.54 GBX1750.00 x
2000-12-31 GBX1.57 GBX1750.00 x
2001-12-31 GBX1.54 GBX1750.00 x
2002-12-31 GBX1.39 GBX1750.00 x
2003-12-31 GBX1.67 GBX1750.00 x
2004-12-31 GBX1.28 GBX1750.00 x
2005-12-31 GBX1.60 GBX1750.00 x
2006-12-31 GBX2.06 GBX1750.00 x
2007-12-31 GBX2.16 GBX1750.00 x
2008-12-31 GBX1.90 GBX1750.00 x
2009-12-31 GBX2.45 GBX1750.00 x
2010-12-31 GBX2.17 GBX1750.00 x
2011-12-31 GBX1.97 GBX1750.00 x
2012-12-31 GBX1.45 GBX1750.00 x
2013-12-31 GBX1.78 GBX1750.00 x
2014-12-31 GBX1.10 GBX1750.00 x
2015-12-31 GBX1.31 GBX1750.00 x
2016-12-31 GBX0.29 GBX1750.00 x
2017-12-31 GBX-0.02 GBX1750.00 x
2018-12-31 GBX0.95 GBX1750.00 x
2019-12-31 GBX2.84 GBX1750.00 x
2020-12-31 GBX3.62 GBX1750.00 x
2021-12-31 GBX4.64 GBX1750.00 x
2022-12-31 GBX2.60 GBX1750.00 x
2023-12-31 GBX3.25 GBX1750.00 x
2024-12-31 GBX3.30 GBX1750.00 x
2025-12-31 GBX3.98 GBX1750.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently GSK plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 34.90%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 17.50%
  • • Asset Turnover: 0.53x
  • • Equity Multiplier: 3.73x
  • Recent ROE (34.90%) is below the historical average (99.33%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1986 36.70% 27.99% 0.79x 1.65x GBX291.00 Million
1987 35.17% 29.29% 0.74x 1.63x GBX365.00 Million
1988 32.57% 28.22% 0.72x 1.61x GBX402.60 Million
1989 30.03% 26.77% 0.74x 1.51x GBX458.90 Million
1990 29.54% 25.39% 0.71x 1.64x GBX533.80 Million
1991 27.46% 25.93% 0.59x 1.79x GBX560.20 Million
1992 28.92% 25.22% 0.72x 1.59x GBX675.80 Million
1993 26.55% 24.48% 0.66x 1.64x GBX752.40 Million
1994 25.85% 22.97% 0.72x 1.57x GBX796.40 Million
1995 253.19% 16.04% 0.80x 19.74x GBX998.26 Million
1995 1602.20% 13.90% 1.23x 93.86x GBX1.45 Billion
1996 163.02% 23.94% 1.00x 6.79x GBX1.87 Billion
1997 100.38% 23.18% 0.95x 4.58x GBX1.67 Billion
1998 67.95% 23.00% 0.85x 3.46x GBX1.57 Billion
1999 57.64% 21.33% 0.81x 3.32x GBX1.50 Billion
2000 53.97% 23.02% 0.84x 2.80x GBX3.39 Billion
2001 41.15% 15.10% 0.93x 2.92x GBX2.35 Billion
2002 59.79% 18.55% 0.95x 3.39x GBX3.28 Billion
2003 58.24% 20.94% 0.90x 3.11x GBX3.72 Billion
2004 66.51% 19.55% 0.88x 3.85x GBX3.32 Billion
2005 64.15% 21.65% 0.80x 3.72x GBX3.96 Billion
2006 57.43% 23.20% 0.91x 2.72x GBX4.45 Billion
2007 54.24% 22.95% 0.73x 3.23x GBX4.25 Billion
2008 58.03% 18.90% 0.62x 4.97x GBX3.81 Billion
2009 55.28% 19.50% 0.66x 4.28x GBX4.53 Billion
2010 18.39% 5.76% 0.67x 4.75x GBX745.30 Million
2011 65.50% 19.21% 0.67x 5.11x GBX4.46 Billion
2012 77.57% 17.02% 0.64x 7.15x GBX3.92 Billion
2013 77.69% 20.51% 0.63x 6.01x GBX4.74 Billion
2014 64.65% 11.98% 0.57x 9.54x GBX2.33 Billion
2015 164.69% 35.20% 0.45x 10.45x GBX7.91 Billion
2016 81.14% 3.27% 0.47x 52.56x GBX799.60 Million
2017 0.00% 5.08% 0.54x 0.00x GBX1.54 Billion
2018 95.82% 11.75% 0.53x 15.36x GBX3.24 Billion
2019 40.73% 13.76% 0.42x 6.99x GBX3.50 Billion
2020 39.41% 16.86% 0.42x 5.51x GBX4.29 Billion
2021 29.13% 17.76% 0.31x 5.25x GBX2.88 Billion
2022 141.12% 51.00% 0.49x 5.68x GBX13.90 Billion
2023 36.92% 16.25% 0.51x 4.42x GBX3.59 Billion
2024 18.84% 8.21% 0.53x 4.35x GBX1.21 Billion
2025 34.90% 17.50% 0.53x 3.73x GBX4.08 Billion

Industry Comparison

This section compares GSK plc's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $48,719,000,000
  • Average return on equity (ROE) among peers: 20.99%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
GSK plc (GSK) GBX17.18 Billion 36.70% 2.59x $853.19 Million
AstraZeneca PLC (AZN) $48.72 Billion 20.99% 1.34x $2.26 Billion

About GSK plc

LSE:GSK UK Drug Manufacturers - General
Market Cap
$853.19 Million
GBX7.01 Trillion GBX
Market Cap Rank
#9604 Global
#34 in UK
Share Price
GBX1750.00
Change (1 day)
+0.84%
52-Week Range
GBX1620.00 - GBX2268.00
All Time High
GBX2268.00
Categories
Companies in UK Drug Manufacturers - General
About

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more